Warning Label For Gadolinium Contrast Agents Gets US FDA Panel Backing

Advisory committee agrees that risks of gadolinium retention in the brain and other organs need further study; actor Chuck Norris' wife was among several patients who testified of devastating medical problems following administration of agents.

FDAEntrance_1200x675

A US FDA advisory committee agreed with the agency's plan to add a warning to the labeling of gadolinium-based contrast agents about the potential consequences of gadolinium retention in the brain and other body organs.

The agency has concluded that a causal connection has not been established between gadolinium retention and reported symptoms in patients...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers